###### Strengths and limitations of this study

-   The main strengths of this protocol rely on its carefully designed search strategy, inclusion and exclusion criteria, and time-span coverage.

-   The search strategy will address the potential EU studies published in non-English national languages, and we will include currently accepted myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) case definitions, to minimise selection bias.

-   Studies based on self-report will be excluded, and the search time of 10 years will enable us to picture the ME/CFS occurrence in Europe.

-   The European Network on ME/CFS (EUROMENE), a network of established researchers on ME/CFS, will conduct the proposed systematic review which can increase credibility and reliability of the findings.

-   A potential limitation of this review may be a small number of studies available and their potential high heterogeneity.

Introduction {#s1}
============

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has heterogeneous clinical features and is characterised by severe fatigue lasting for at least 6 months that is medically unexplained and not relieved by resting.[@R1] Consequently, ME/CFS often imposes a huge burden on daily life with negative impacts on health-related quality of life, labour status, and social and familial relationships.[@R2] Societal disbeliefs may add to the burden for people with ME/CFS.[@R3]

For several reasons, ME/CFS is a challenge for scientists. First, to date, the features of ME/CFS have been poorly defined. For instance, an intense physical discomfort (ie, malaise) along with flares of ME/CFS symptoms (lasting for longer than 24 hours) is observed after minimum physical exertion.[@R6] However, whether post-exertional malaise is a distinctive feature of ME/CFS is not yet fully agreed.[@R7] Second, related to the lack of consensus on its defining features, a large number of disparate criteria for the diagnosis of ME/CFS are currently used worldwide.[@R8] Indeed, the most common scenario is to diagnose ME/CFS after exclusion of other diseases.[@R4] Third, as different diagnostic criteria are used, ME/CFS prevalence and incidence figures are highly variable across studies. For instance, within an Icelandic study,[@R14] the prevalence of ME/CFS ranged from 0% to 5% by means of the Lloyd *et al* [@R15] or Holmes *et al* [@R16] criteria, respectively.

To address the above-mentioned caveats and others, it is imperative to understand ME/CFS comprehensively. With this purpose, the European Network on ME/CFS (EUROMENE) was established. This (EU-funded COST Action; Reference number: 15111) multidisciplinary network involves patients, stakeholders, researchers, clinicians and industry. We intend to align ME/CFS research within the established landscape of European biomedical research by developing additional proposals to the new H2020 and further Framework programme collaborative research projects. Further information about the EUROMENE network is available at <http://www.cost.eu/COST_Actions/ca/CA15111> and <http://www.euromene.eu/>.

EUROMENE consists of six closely coordinated working groups. Working group 1 focuses on the epidemiology of ME/CFS and leads the European Epidemiological Study for ME/CFS (Euro-EpiME study). One specific aim of this study is to estimate the prevalence and incidence of ME/CFS in Europe. As a first step, we will systematically review the available literature from European countries in order to provide a robust summary and identify new challenges in the field. It seems likely that more data on the prevalence and incidence of ME/CFS will be needed, both for Europe as a whole and within the European countries. Previously, systematic reviews have been conducted including studies from many parts of the world.[@R17] However, these previous reviews: (1) were conducted more than 5 years ago,[@R20] (2) did not report the incidence of ME/CFS and (3) did not include children or adolescents.

Objective {#s1a}
---------

We aim to conduct a systematic review and, if possible, meta-analyses to determine the prevalence and incidence of ME/CFS in Europe.

Review question {#s1b}
---------------

1.  What is the prevalence of ME/CFS in Europe?

2.  What is the incidence of ME/CFS in Europe?

Methods {#s2}
=======

Inclusion criteria {#s2a}
------------------

1.  Studies reporting either the prevalence or incidence of ME/CFS, including any of the following clinical diagnostic criteria: CDC-1994,[@R9] Canadian Consensus Criteria,[@R1] London Criteria,[@R21] International Consensus Criteria[@R10] or Institute of Medicine criteria,[@R22] irrespective of age groups.

2.  Studies from European countries.

3.  Studies in community or primary care settings.

Exclusion criteria {#s2b}
------------------

1.  Studies without primary data (eg, reviews).

2.  Studies conducted in biased samples (eg, vaccines, virus infection, veterans).

3.  Studies based on self-report of the diagnosis of ME/CFS.

4.  Studies with an inappropriate case definition (eg, CFS-like illness or other clinical criteria, such as the Oxford criteria due to lack of specificity).

5.  Duplicate reports. When populations are overlapping, the study with the largest sample size will be included.

6.  Studies published more than 10 years ago (ie, before 2008).

No language restriction will be applied.

Search strategy for identifying relevant studies {#s2c}
------------------------------------------------

The search strategy will consist of two stages: a primary systematic literature search on three electronic databases and a complementary search.

### The primary systematic literature search on electronic databases {#s2c1}

Two independent reviewers (FE-L and JC-M) will perform a primary electronic search in PubMed, Scopus and Web of Science on 9 January 2018. [Table 1](#T1){ref-type="table"} shows the search strategy.

###### 

The primary systematic literature search strategy on the electronic databases

  Database         Search terms combination
  ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Scopus           ({epidemiology} OR {prevalence} OR {incidence}) AND ({chronic fatigue syndrome} OR {myalgic encephalomyelitis} OR {CFS/ME} OR {ME/CFS})
  PubMed           (\"Fatigue Syndrome, Chronic\"\[Mesh\] AND ((\"Incidence\" \[Mesh\] OR \"Epidemiology\"\[Mesh\] OR \"epidemiology\" \[Subheading\] OR \"Prevalence \"\[Mesh\] OR \"Cross-Sectional Studies \"\[Mesh\]))
  Web of Science   (\"epidemiology\" OR \"prevalence\" OR \"incidence\") AND (\"chronic fatigue syndrome\" OR \"myalgic encephalomyelitis\" OR \"CFS/ME\" OR \" ME/CFS\")

Mesh, medical subject headings.

### The complementary search {#s2c2}

We will conduct a twofold complementary search as follows: first, we will perform a backward (by checking reference lists) and forward (by checking citations) search of the works included in the present review; and second, grey literature will be addressed by contacting---via email---all the members of EUROMENE to provide, if available, prevalence rates, incidence rates or both of ME/CFS in their countries according to national registers, publications in their own languages or any other publicly accessible source.

Selection of studies for inclusion to the review {#s2d}
------------------------------------------------

Two independent researchers (FE-L and JC-M) will screen records retrieved by the electronic search by titles/abstracts or full text of works for identifying potential studies and their suitability. When disagreements emerge between the two independent researchers, consensus will be obtained through discussion or when required, the opinion of a third researcher (IJB) will be considered.

Assessment of methodological quality and reporting of data {#s2e}
----------------------------------------------------------

The methodological quality of the eligible studies will be evaluated with the Joanna Briggs Institute-Checklist for Prevalence Studies.[@R23] Before applying it, six members of the research team (ie, FE-L, LN, JA, SS, EL and MM) will develop an agreed appraisal of the tool. This appraisal will be published with the review as supplementary information. The reporting quality of the eligible studies will be evaluated using the Strengthening the Reporting of Observational Studies in Epidemiology checklist.[@R24] Two independent researchers (ie, AI and XW) will evaluate the methodological and reporting quality of the included works. When controversies emerge, studies will be discussed with two other members of the team in order to reach a consensus (ie, EBS and DP for methodological and reporting quality, respectively). The quality assessment will be considered when discussing the findings.

Data extraction and management {#s2f}
------------------------------

To manage the retrieved records from the electronic search, we will use the Mendeley Desktop. Two independent researchers (FE-L and AI) will extract the following relevant data from the included studies: reference (authors and year of publication), country (city or region when relevant), design (ie, general population online survey), total sample size (n and % of women, n and % of migrants), age range, setting (eg, primary care), case definition (ie, diagnosis criteria), dates of data collection, overall prevalence and/or incidence and prevalence and/or incidence by gender and age groups (when available). When discrepancies emerge in the coding between the two researchers' results, these will be discussed with another members of the team (ie, NS) to reach a consensus.

Data synthesis and analysis {#s2g}
---------------------------

We anticipate that studies on the prevalence and incidence of ME/CFS in Europe will prove to be scarce and heterogeneous. The preliminary findings of the review will be presented in a EUROMENE meeting (ie, September 2018, in London, UK) where we will discuss the appropriateness of performing meta-analyses.

A narrative (descriptive) synthesis is planned if meta-analyses are not feasible. We will pay special attention to possible factors related to heterogeneity of the findings in order to find patterns that should be considered in future research. For instance, we will discuss whether the prevalence or incidence of ME/CFS differ according to the case definition used to examine the figures. Attention will be also paid to the characteristics of the studied populations (eg, age group, gender).

We will undertake meta-analyses only where pooling of quantitative data is possible. The meta regression analysis will be performed to investigate the sources of heterogeneity of any ME/CFS pooled prevalence and incidence estimate. The I^2^ statistic will be used to investigate the heterogeneity. I^2^ of 25%, 50% and 75% will be appraised as low, moderate and high, respectively.[@R25]

Presentation and reporting of results {#s2h}
-------------------------------------

We will report the findings of the present literature review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@R26] A flow diagram ([figure 1](#F1){ref-type="fig"}) will illustrate the process of study selection from retrieved records to included studies. For transparency purposes, supplementary files will show which studies were excluded at every stage of the review. If the present protocol needs amendments, they will be publicly available along with their rationale on the EUROMENE website (<http://www.euromene.eu/>).

![Flow diagram for study selection. ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; WOS, Web of Science.](bmjopen-2017-020817f01){#F1}

In accordance with the data extraction, a table will show the main characteristics of the studies included. Information on the quality of the methodology and reporting of the studies will also be available.

If meta-analyses are performed, we plan using comprehensive meta-analysis to combine data of prevalence or incidence from different studies to estimate the mean effect. We will select an appropriate model in terms of studies that we include and calculate pooled ME/CFS prevalence and incidence. We will compare the results of random-effects and fixed-effect meta-analyses in sensitivity analyses.

Ethics and dissemination {#s2i}
------------------------

The findings of this systematic review will address a specific aim of the European network EUROMENE (ie, to summarise the available data of the prevalence and incidence of ME/CFS in Europe). The findings will be included in EUROMENE reports published in paper(s) in peer-reviewed journal(s) and presented at conferences and meetings.

The findings of the present systematic review will be widely communicated to society using mass media (eg, interviews on radio, newspaper, television and the internet). Since our findings may have an impact on policy and healthcare practice, we will also present them to policy-makers and healthcare providers.

Patient and public involvement {#s2j}
------------------------------

EUROMENE is multidisciplinary network cooperating with patient organisations via Web platform. Patient organisations are benefiting from dedicated events, dedicated printed media and interaction through social media. We will present our findings to patients with ME/CFS (eg, by direct communication with representative patient organisations and by giving talks to local associations of people with ME/CFS). General public will be reached through the COST Action website, oral presentations and interviews.

Supplementary Material
======================

###### Reviewer comments
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